慢性乙型肝炎病毒感染者血清MIF、IL-17和IL-10水平变化*

doi:10.3969/j.issn.1672-5069.2015.01.018

Abstract

Li Caidong, Yang Yongwei, Tian Pengfei, et al. Changes of serum macrophage migration inhibitory factor, IL-17 and IL-10 levels in patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 71-73.

References

[1] Mitchell RA. Mechanisms and effectors of MIF dependent promotion of tumourigenesis. Cell Signal,2004,16（1）:13-19.
[2] Ge J,Wang K,Meng QH,et al. Implication of Thl7 and Thl cells in patients with chronic active hepatitis B. J Clin Immunol,2010,30（1）:60-67.
[3] Ouyang W,Rutz S,Crellin NK,et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease . Annu Rev Immunol,2011,29:71-109.
[4] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[5] Heinrichs D,Knauel M,Offermanns C,et al. Macrophage migration inhibitory factor（MIF） exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci USA,2011,108（42）:17444-17449.
[6] 晁康, 龚晓蓉, 陈旻湖,等. Th17细胞在肝脏疾病中的免疫病理作用. 实用肝脏病杂志,2010,13（3）:224-227.
[7] Zhang JY,Zhang Z,Lin F,et al. Interleukin-17-producing CD4（+） T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology,2010,51:81-91.
[8] 任劲松, 潘修成, 李丽, 等. 慢性乙型肝炎患者外周血Th17细胞和IL-17检测及其临床意义. 中华临床医师杂志,2011,5: 4264-4267.
[9] Arnaud V,Li J,Wang Y,et al. Regulatory role of interleukin-10 and interferon- gamma in severe hepatic central and peripheral fibrosis in humans infected with Schistosoma japonicum. J Infect Dis,2008,198:418-426.
[10] Wasmuth HE,Kunz D,Yagmur E,et al. Patients with acute on chronic liver failure display“sepsis-like” immune paralysis. J Hepatol,2005,42:195-201
[11] Li J,Wu W,Peng G,et al. HBcAg induces interleukin-10 production, inhibiting HBcAg-specific Th17 responses in chronic hepatitis B patients. Immunol Cell Biol,2010,88:834-841.
[12] 曹忆嵘,彭利军,欧阳阳阳,等. 乙型肝炎病毒感染患者肝硬化发生相关临床危险因素评价. 肝脏,2013,18（4）:211-215.
[13] 赵攀,毕振华,王春亚. 急性肝衰竭患者血清炎性细胞因子水平分析. 实用肝脏病杂志,2014,17（1）:63-64.
[14] 李晨,邢少军,段学章,等. 乙型肝炎肝硬化患者外周血调节性T细胞频率及血清IL-1β、IL-6和IL-10水平的变化. 实用肝脏病杂志,2012,15（3）:244-246.
[15] 孙彤,陈凯红,裴豪,等. 康艾注射液对代偿期肝硬化患者多种细胞因子的影响. 中西医结合肝病杂志,2012,22:210-214.

Changes of serum macrophage migration inhibitory factor, IL-17 and IL-10 levels in patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[4]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[5]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[6]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[7]	Jin Jun, Song Zhenyu, Liu Jixiang. Changes of serum IL-10 and soluble intercellular adhesion molecule-1 levels in patients with hepatitis B-induced liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 549-552.
[8]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[9]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[10]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[11]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[12]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[13]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.
[14]	Zhou Zhiling, Yin Qian.. Forecasting hepatic activity index and liver fibrosis staging by serum golgiprotein-73 levels in individuals with chronic hepatitis B viral carriers [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 717-720.
[15]	Wang Fangfang, Zhang Guofan, Guo Chunxia, et al.. Clinical efficacy and safety of switching from entecavir to interferon-α in patients with hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 721-724.